Quantcast

Latest Daiichi Sankyo Stories

2011-08-17 08:59:00

PARSIPPANY, N.J., Aug. 17, 2011 /PRNewswire/ -- With the US Food and Drug Administration (FDA) approval today of Zelboraf(TM) (vemurafenib), a first-in-class personalized treatment for patients with unresectable (inoperable) or metastatic melanoma with a BRAF V600E mutation as detected by an FDA-approved test, Daiichi Sankyo prepares to enter the US cancer market with its first oral, targeted anti-cancer therapy. "The Zelboraf approval is not only a significant milestone for these...

2011-08-17 07:30:00

PARSIPPANY, N.J., Aug. 17, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc. announced that Mahmoud Ghazzi, MD, PhD has joined Daiichi Sankyo Pharma Development (DSPD) as its new executive vice president of drug development for the Americas region. DSPD, headquartered in Edison, NJ, is responsible for the regional delivery of global clinical trials throughout North, South and Central America. Dr. Ghazzi will work closely with the global development regional heads in Asia, Japan and Europe to...

2011-07-26 00:00:00

BARCELONA, Spain and GERRARDS CROSS, England, July 26, 2011 /PRNewswire/ -- Veeva Systems announced today that Daiichi Sankyo, one of the world's top 20 pharmaceutical companies, is replacing its legacy, on-premise Customer Relationship Management (CRM) system with Veeva CRM in the UK. Daiichi Sankyo will deploy Veeva CRM to all of its commercial teams in the UK including integrated healthcare, specialty care, medical liaison scientists, and head-office teams (i.e., marketing...

2011-07-25 11:36:00

PARSIPPANY, N.J., July 25, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) for Oral Suspension to be mixed with fruit juice or diet soft drinks, offering a new option for adult patients with primary hyperlipidemia and type 2 diabetes. Welchol for Oral Suspension was first approved in 2009 to be mixed with water. Welchol is...

2011-07-19 07:00:00

TOKYO, July 19, 2011 /PRNewswire/ -- Building on its cardiovascular portfolio, Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), is proud to announce the launch of LIXIANA® (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban) in Japan. This announcement follows the first marketing approval for edoxaban 15 mg and 30 mg tablets by the Japanese Ministry of Health, Labor and Welfare in April 2011 (1), and marks the first time edoxaban is commercially available to...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related